Estrogen alone and joint symptoms in the women's health initiative randomized trial

Menopause

Volumn 20, Issue 6, 2013, Pages 600-608

  Chlebowski, Rowan T ^a   Cirillo, Dominic J ^b   Eaton, Charles B ^c   Stefanick, Marcia L ^d   Pettinger, Mary ^e   Carbone, Laura D ^f   Johnson, Karen C ^f   Simon, Michael S ^g   Woods, Nancy F ^h   Wactawski Wende, Jean ⁱ  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY AT BUFFALO   (United States)

Author keywords

Estrogen; Joint pain; Joint swelling; Postmenopausal women; Randomized clinical trial; Women's Health Initiative

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTHROPATHY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HYSTERECTOMY; JOINT SWELLING; MAJOR CLINICAL STUDY; POSTMENOPAUSE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; WOMEN'S HEALTH;

AGED; ARTHRALGIA; CALCIUM; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; QUESTIONNAIRES; VITAMIN D; WOMEN'S HEALTH;

EID: 84879144668     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31828392c4     Document Type: Article

References (43)

1. Magliano M. Menopausal arthralgia: Fact or fiction. Maturitas 2010; 67:29-33.
2. Szoeke CE, Circuttini FM, Guthrie JR, Dennerstein L. The relationship of reports of aches and joint pains to the menopausal transition: A longitudinal study. Climacteric 2008;11:55-62.
3. de Klerk BM, Schiphof D, Groeneveld FPMJ, et al. Limited evidence for a protective effect of unopposed oestrogen therapy for osteoarthritis of the hip: A systemic review. Rheumatology (Oxford) 2009a;48:104-112.
4. Roman-Blas JA, Castaneda S, Largo R, Herrero-Beaumont G. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther 2009;11:241.
5. Szoeke CE, Circuttini FM, Guthrie JR, Clark MS, Dennerstein L. Factors affecting the prevalence of osteoarthritis in healthy middle-aged women: Data from the longitudinal Melbourne Women's Midlife Health Project. Bone 2006;39:1149-1155.
6. Nevitt MC, Cummings SR, Lane NE, et al. For the Study of Osteoporotic Fractures Research Group. Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Arch Intern Med 1996;156:2073-2080.
7. Wluka AE, Davis SR, Bailey M, Stuckey SL, Cicuttini FM. Users of oestrogen replacement therapy have more knee cartilage than non-users. Ann Rheum Dis 2001;60:332-336.
8. Richette P, Corvol M, Bardin T. Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 2003;70:257-262.
9. Hannan MT, Felson DT, Anderson JJ, Naimark A, Kannel WB. Estrogen use and radiographic osteoarthritis of the knee in women: The Framingham Osteoarthritis Study. Arthritis Rheum 1990;33:525-532.
10. Zhang Y, McAlindon TE, Hannan MT, et al. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: The Framingham Study. Arthritis Rheum 1998;41:1867-1873.
11. Erb A, Brenner H, Gunther KP, Sturmer T. Hormone replacement therapy and patterns of osteoarthritis: Baseline data from the Ulm Osteoarthritis Study. Ann Rheum Dis 2000;59:105-109.
12. Carbone LD, Nevitt MC, Wildy K, et al. The relationship of anti-resorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004;50:3516-3525.
13. de Klerk BM, Schiphof D, Groeneveld FPMJ, et al. No clear association between female hormonal aspects and osteoarthritis of the hand, hip and knee: A systematic review. Rheumatology 2009;48:1160-1165.
14. Brunner RL, Aragaki A, Barnabei V, et al. Menopausal symptoms experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause 2010; 17:946-954.
15. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
16. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health risks and benefits 5 years after stopping randomized treatment with conjugated equine estrogens in postmenopausal women with prior hysterectomy. JAMA 2011; 305:1305-1314.
17. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-1657.
18. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: Extended follow-up of the Women's Health Initiative randomized placebo-controlled trial. Lancet Oncol 2012; 13:476-486.
19. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: Results from the Women's Health Initiative randomized trial. J Bone Miner Res 2006;21:817-828.
20. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-696.
21. Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008; 100:1604-1616.
22. McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women. JAMA 2003;290:1331-1336.
23. Patterson RE, Kristal AR, Tinker LF, et al. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol 1999;9:178-187.
24. Kirk KM, Bellamy N, O'Gormon LE, et al. The validity and heritability of self-report osteoarthritis in an Australian older twin sample. Twin Res 2002;5:98-106.
25. March LM, Schwarz JM, Carfrae BH, Bagge E. Clinical validation of self-reported osteoarthritis. Osteoarthritis Cartilage 1998;6:87-93.
26. Taal E,Abdel-Nasser AM, Rasker JJ,Wiegman O. A self-report Thompson articular index: What does it measure? Clin Rheumatol 1998;17:125-129.
27. Walitt B, Pettinger M, Weinstein A, et al. Effects of postmenopausal hormone therapy on rheumatoid arthritis: The Women's Health Initiative randomized controlled trials. Arthritis Rheum 2008;59:302-310.
28. Crillo DJ, Wallace RB, Wu L, Yood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. Arthritis Rheum 2006;54:3194-3204.
29. Sowers MR, McConnell D, Jannausch M, Buyuktur AG, Hochberg M, Jamadar DA. Estradiol and its metabolites and their association with knee osteoarthritis. Arthritis Rheum 2006;54:2481-2487
30. Gao W, Zeng C, Cai D, Liu B, Wen X, Chen Y. Serum concentrations of selected endogenous estrogen and estrogen metabolites in pre-and post-menopausal Chinese women with osteoarthritis. J Endocrinol Invest 2010;33:644-649.
31. Tanamas SK, Wijethilake P, Wluka AE, et al. Sex hormones and structural changes in osteoarthritis: A systematic review. Maturitas 2011;69:141-156.
32. Jochems C, Islander U, Erlandsson M, et al. Osteoporosis in experimental postmenopausal polyarthritis: The relative contributions of estrogen deficiency and inflammation. Arthritis Res Ther 2005;7:R837-R843.
33. Hoegh-Andersen P, Tanko LB, Andersen TL, et al. Ovariectomized rats as a model of postmenopausal osteoarthritis: Validation and application. Arthritis Res Ther 2004;6:R169-R180.
34. Ham KD, Loeser RF, Lindgren BR, Carlson CS. Effects of long term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 2002;46:1956-1964.
35. Mouritzen U, Christgau S, Lehmann HJ, Tanko LB, Christiansen C. CartiLaps. A novel marker of cartilage degradation. The influence of age, gender, menopause, hormone replacement therapy and bone mass index. Ann Rheum Dis 2003;62:332-336
36. Josse RG. Roles for estrogen in bone loss and arthralgia during aromatase inhibitor treatment. Curr Opin Oncol 2007;19:S1-S8.
37. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477
38. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751-757.
39. The Arimidex, Tamoxifen, Alone or in Combination Trialists Group. Buzdar AM, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633-643.
40. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgia with estrogen deprivation. Arthritis Rheum 2005;52:2594-2598.
41. Chlebowski RT. Aromatase inhibitorYassociated arthralgias. J Clin Oncol 2009;27:4932-4934.
42. Chlebowski RT, Col N. Menopausal hormone therapy after breast cancer. Lancet 2004;363:410-411.
43. Col NF, Kim JA, Chlebowski RT. Menopausal hormone therapy in breast cancer survivors: A meta-analysis and critical appraisal of the evidence. Breast Cancer Res 2005;42:861-872.